Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
Full name:
Authorised dose form:
Legal status of supply:
Domain:
Resource status:
Product classification:
Document Details
Generated Narrative: Bundle TEST PURPOSES ONLY - ammonaps
Language: en
Profile: Bundle - ePI
Final Document at 2022-02-16 13:28:17+0000 by Organization ACME industry for Bundle: identifier = http://ema.europa.eu/identifier#None; type = document; timestamp = 2023-06-27 10:09:22+0000
Document Subject
Generated Narrative: MedicinalProductDefinition mp36d93771f3347f288be457a7d33515c7
identifier: http://ema.europa.eu/identifier
/EU/1/99/120/001 (250 tablets)
type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: AMMONAPS 500 mg tablets.
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en
Document Content
Generated Narrative: Composition composition-en-36d93771f3347f288be457a7d33515c7
Language: en
Profile: Composition (ePI)
identifier: http://ema.europa.eu/identifier
/EU/1/99/120/001 (250 tablets)
status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - ammonaps
Mode | Time |
Official | 2022-02-16 13:28:17+0000 |
What is in this leaflet
AMMONAPS is prescribed to patients with urea cycle disorders. Patients with these rare disorders have a deficiency of certain liver enzymes and are therefore unable to eliminate nitrogen waste. Nitrogen is a building block of proteins, because of this, there is a build up of nitrogen in the body after eating protein. Nitrogen waste, in the form of ammonia, is especially toxic for the brain and leads, in severe cases, to reduced levels of consciousness and to coma.
AMMONAPS helps the body to eliminate nitrogen waste, reducing the amount of ammonia in your body.
Do not take AMMONAPS
if you have difficulty swallowing. AMMONAPS tablets can get stuck in the oesophagus and cause ulcers. If you have difficulty swallowing it is recommended to use AMMONAPS granules instead.
AMMONAPS must be combined with a diet reduced in proteins designed especially for you by the doctor and the dietician. You must follow this diet carefully. AMMONAPS does not completely prevent the occurrence of an acute excess of ammonia in the blood and is not appropriate for treating such a condition, which is a medical emergency.
If you require laboratory tests, it is important to remind your doctor that you are taking AMMONAPS, since sodium phenylbutyrate may influence certain laboratory test results.
Other medicines and AMMONAPS Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.
It is especially important to tell your doctor if you are taking medicines containing:
These medicines may change the effect of AMMONAPS and you will need more frequent blood controls. If you are uncertain if your medicines contain these substances, you should check with your doctor or pharmacist.
Pregnancy and breast-feeding Do not use AMMONAPS if you are pregnant, because this medicine can harm your unborn baby. If you are a woman who could get pregnant, you must use reliable contraception, during treatment with AMMONAPS. Do not use AMMONAPS if you are breast-feeding, because this medicine can pass into the breast- milk and harm your baby.
Driving and using machines No studies on the effects on the ability to drive and use machines have been performed.
AMMONAPS contains sodium Each AMMONAPS tablet contains 62 mg of sodium.
Talk to your doctor or pharmacist if you need 6 or more tablets daily for a prolonged period, especially if you have been advised to follow a low salt (sodium) diet.
Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.
Dosage The daily dose of AMMONAPS will be calculated from your protein tolerance, diet and body weight or body surface. You will need regular blood tests to determine the correct daily dose. Your doctor will tell you how many tablets you should take.
Method of administration You should take AMMONAPS by mouth in equally divided doses with each meal (for example three times per day). You should take AMMONAPS with a large volume of water.
AMMONAPS must be taken with a special diet reduced in protein.
AMMONAPS tablets should not be given to children who are not able to swallow tablets. It is recommended that AMMONAPS granules are used instead.
You will need to have treatment and to follow a diet throughout your life, unless you have a successful liver transplantation.
If you take more AMMONAPS than you should Patients who have taken very high doses of AMMONAPS experienced:
If you experience any of these symptoms, you should immediately contact your doctor or the nearest hospital emergency department for supportive treatment.
If you forget to take AMMONAPS You should take a dose as soon as possible with your next meal. Make sure that there are at least 3 hours between two doses. Do not take a double dose to make up for a forgotten dose.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
The frequency of possible side effects is listed below.
Very common:
Affects more than 1 user in Common:
Affects 1 to 10 users in Uncommon:
Affects 1 to 10 users in 1,Rare:
Affects 1 to 10 users in 10,Very rare:
Affects less than 1 user in 10,Not known:
Frequency cannot be estimated from the available data
Very common side effects: irregular menstrual periods and cessation of menstrual periods.
If you are sexually active and your period stops altogether, do not assume that this is caused by AMMONAPS. If this occurs, please discuss it with your doctor, because the absence of your period may be caused by pregnancy (see Pregnancy and breast-feeding section above).
Common side effects: changes in number of blood cells (red cells, white cells and platelets), reduced appetite, depression, irritability, headache, fainting, fluid retention (swelling), changes in taste (taste disturbances), pain in the abdomen, vomiting, nausea, constipation, skin odour, rash, abnormal kidney function, weight gain, altered laboratory test values.
Uncommon side effects: deficiency in red blood cells due to bone marrow depression, bruising, altered heart rhythm, rectal bleeding, stomach irritation, stomach ulcer, inflammation of the pancreas.
If persistent vomiting occurs, you should contact your doctor immediately.
Reporting of side effects If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton and the bottle label after EXP . The expiry date refers to the last day of that month.
Do not store above 30 C.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
What AMMONAPS contains
What AMMONAPS looks like and contents of the pack AMMONAPS tablets are off-white, oval and embossed with UCY 500 .
The tablets are packaged in plastic bottles with child-resistant caps. Each bottle contains 250 or 500 tablets.
Marketing Authorisation Holder
Immedica Pharma AB SE-113 63 Stockholm Sweden
Manufacturer PATHEON France BOURGOIN JALLIEU 40 boulevard de Champaret BOURGOIN JALLIEU 38France
This leaflet was last revised in
Detailed information on this medicine is available on the European Medicines Agency web site:
Entry 1 - fullUrl = Composition/composition-en-36d93771f3347f288be457a7d33515c7
Resource Composition:
Generated Narrative: Composition composition-en-36d93771f3347f288be457a7d33515c7
Language: en
Profile: Composition (ePI)
identifier:
http://ema.europa.eu/identifier
/EU/1/99/120/001 (250 tablets)status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - ammonaps
Attesters
Mode Time Official 2022-02-16 13:28:17+0000
Entry 2 - fullUrl = MedicinalProductDefinition/mp36d93771f3347f288be457a7d33515c7
Resource MedicinalProductDefinition:
Generated Narrative: MedicinalProductDefinition mp36d93771f3347f288be457a7d33515c7
identifier:
http://ema.europa.eu/identifier
/EU/1/99/120/001 (250 tablets)type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: AMMONAPS 500 mg tablets.
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en